Northern Trust’s Takeda Pharmaceutical TAK Stock Holding History

Northern Trust’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$36.3M	Buy	1,961,038 +262,123	+15%	+$4.6M	﹤0.01%	1314
2025 Q4	$26.5M	Sell	1,698,915 -124,795	-7%	-$1.78M	﹤0.01%	1492
2025 Q3	$26.7M	Sell	1,823,710 -206,175	-10%	-$3.06M	﹤0.01%	1509
2025 Q2	$31.4M	Buy	2,029,885 +389,972	+24%	+$5.76M	﹤0.01%	1384
2025 Q1	$24.4M	Sell	1,639,913 -233,675	-12%	-$3.27M	﹤0.01%	1508
2024 Q4	$24.8M	Buy	1,873,588 +238,161	+15%	+$3.27M	﹤0.01%	1564
2024 Q3	$23.3M	Buy	1,635,427 +44,902	+3%	+$637K	﹤0.01%	1527
2024 Q2	$20.6M	Sell	1,590,525 -275,628	-15%	-$3.65M	﹤0.01%	1546
2024 Q1	$25.9M	Buy	1,866,153 +51,994	+3%	+$756K	﹤0.01%	1409
2023 Q4	$25.9M	Sell	1,814,159 -376,111	-17%	-$5.34M	﹤0.01%	1438
2023 Q3	$33.9M	Sell	2,190,270 -84,881	-4%	-$1.31M	0.01%	1189
2023 Q2	$35.7M	Sell	2,275,151 -486	-0%	-$7.96K	0.01%	1194
2023 Q1	$37.5M	Sell	2,275,637 -105,217	-4%	-$1.68M	0.01%	1137
2022 Q4	$37.1M	Buy	2,380,854 +188,267	+9%	+$2.63M	0.01%	1129
2022 Q3	$28.4M	Sell	2,192,587 -67,532	-3%	-$939K	0.01%	1229
2022 Q2	$31.7M	Buy	2,260,119 +40,761	+2%	+$582K	0.01%	1209
2022 Q1	$31.8M	Sell	2,219,358 -120,979	-5%	-$1.78M	0.01%	1355
2021 Q4	$31.9M	Buy	2,340,337 +77,503	+3%	+$1.09M	0.01%	1442
2021 Q3	$37.1M	Sell	2,262,834 -1,970,848	-47%	-$33.1M	0.01%	1320
2021 Q2	$71.3M	Sell	4,233,682 -325,344	-7%	-$5.54M	0.01%	858
2021 Q1	$83.2M	Buy	4,559,026 +179,997	+4%	+$3.24M	0.02%	758
2020 Q4	$79.7M	Buy	4,379,029 +132,842	+3%	+$2.33M	0.02%	752
2020 Q3	$75.8M	Buy	4,246,187 +429,250	+11%	+$7.82M	0.02%	679
2020 Q2	$68.4M	Buy	3,816,937 +403,825	+12%	+$7.25M	0.02%	693
2020 Q1	$51.8M	Sell	3,413,112 -332,342	-9%	-$6.02M	0.01%	757
2019 Q4	$73.9M	Sell	3,745,454 -170,219	-4%	-$3.26M	0.02%	740
2019 Q3	$67.3M	Sell	3,915,673 -147,635	-4%	-$2.55M	0.02%	752
2019 Q2	$71.9M	Sell	4,063,308 -155,542	-4%	-$2.83M	0.02%	740
2019 Q1	$85.9M	Buy	4,218,850 +803,851	+24%	+$16.2M	0.02%	622
2018 Q4	$57.4M	Buy	+3,414,999	New	+$57.7M	0.02%	764

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust's TAK Position: Q1 2026 in Review

Northern Trust increased its Takeda Pharmaceutical (TAK) stake by 15% in Q1 2026, buying an estimated $4.6M and bringing the position to 1,961,038 shares worth $36.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1314.

Northern Trust first reported a position in TAK in Q4 2018 and has held it in 30 quarters since. The position peaked at $85.9M in Q1 2019. 359 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Northern Trust held 1,961,038 shares of Takeda Pharmaceutical worth $36.3M as of Q1 2026.
Northern Trust bought 262,123 Takeda Pharmaceutical shares in Q1 2026, an estimated $4.6M.
Takeda Pharmaceutical made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1314 holding.
Northern Trust first reported a position in Takeda Pharmaceutical in Q4 2018 and has held it in 30 quarters since.
Northern Trust's Takeda Pharmaceutical position peaked at $85.9M in Q1 2019.
359 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.